Biobanking of fresh-frozen endoscopic biopsy specimens from XXXX .

@entity1 @entity1568 @entity5 @entity418 @entity420
UNASSIGNED: The process of preparing endoscopic @entity420 samples for next-generation DNA/RNA sequencing is poorly described. Therefore, we assessed the feasibility and pitfalls of preparing @entity420 endoscopic biopsies toward DNA/RNA samples suitable for next-generation sequencing. In this prospective study, four @entity5 biopsy samples were collected from consecutive @entity418 @entity1 during esophagogastroduodenoscopy and fresh-frozen in liquid @entity1568 . DNA and RNA were isolated from samples with a @entity5 percentage of at least 50%. For next-generation sequencing, double-stranded DNA (dsDNA) is required and high-quality RNA preferred. The quantity dsDNA and RNA quantity and quality were assessed with the Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). Biopsy samples of 69 consecutive @entity1 with @entity420 were included. In five @entity1 (7%), the @entity5 percentage was less than 50% in all four biopsies. Using a protocol allowing simultaneous DNA and RNA isolation, the median dsDNA yield was 2.4    g (range 0.1-12.0    g) and the median RNA yield was 0.5    g (range 0.01-2.05    g). The median RNA integrity number of samples that were fresh-frozen within 30 minutes after sampling was 6.7 (range 4.2-8.9) compared with 2.5 (1.8-4.5) for samples that were fresh-frozen after 2 hours. The results from this study show that obtaining dsDNA and RNA for next-generation sequencing from endoscopic @entity420 samples is feasible. @entity5 percentage and dsDNA/RNA yield and quality emphasize the need for sampling multiple biopsies and minimizing the delay before fresh-freezing.
